Zu den Deals
Gesundheitswesen

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

Parteien

Sprechen Sie mit dem Deal-Team

Giulio Greco

Geschäftsführer
Mailand, Italien
Oaklins Italy

Nicola Vulcano

Director
Mailand, Italien
Oaklins Italy

Marco Valsecchi

Associate
Mailand, Italien
Oaklins Italy

Rita Vizzi

Analyst
Mailand, Italien
Oaklins Italy

Relevante Transaktionen

Ebidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Private Equity | Maschinen- & Anlagenbau, Komponenten

Ebidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment

Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.

Weitere Informationen
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Gesundheitswesen

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Weitere Informationen
Aedes has finalized a rights issue
Immobilien

Aedes has finalized a rights issue

Aedes S.p.A. has successfully finalized a rights issue to support the objectives of the group’s 2024-2028 business plan and the relaunch of its business.

Weitere Informationen